Soleno Therapeutics Inc
SLNO
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
152
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.20 | 8.10 | 0.09% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,072.24 | 583.65 | 1.20% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,559.01 | 26.05 | -0.10% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,768.80 | 994.16 | 1.88% |
| NZX 50 Index | 13,533.60 | 40.33 | -0.30% |
| S&P 500 | 6,873.77 | 76.91 | 1.13% |
| S&P/ASX 200 | 8,845.10 | 9.20 | 0.10% |
| SSE Composite Index | 4,110.86 | 6.08 | -0.15% |